Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSC | P53634 | 7/20 | 0.55 |
| ▸ | CTSK | P43235 | 5/20 | 0.55 |
| ▸ | GSK3B | P49841 | 2/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 2/20 | 0.44 |
| ▸ | WNT1 | P04628 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 8/20 | 0.42 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22643282 | 0.86 | CTSK (0.49) | CTSCCTSKGSK3BDYRK1AWNT1 | |
| SCHEMBL19155286 | 0.80 | CTSK (0.48) | CTSCCTSKCHRM1CREBBPBRD4 | |
| SCHEMBL19155346 | 0.75 | CTSC (0.55) | CTSCCTSKCHRM1 | |
| SCHEMBL19155068 | 0.75 | CTSC (0.55) | CTSCCTSKCHRM1 | |
| SCHEMBL19155042 | 0.75 | CTSC (0.55) | CTSCCTSKCHRM1 | |
| SCHEMBL19368289 | 0.74 | CTSC (0.52) | CTSCCTSKCHRM1 | |
| SCHEMBL19368384 | 0.74 | CTSC (0.53) | CTSCCTSKCHRM1 | |
| SCHEMBL17794957 | 0.74 | CHRM1 (0.59) | CHRM1 | |
| SCHEMBL24958712 | 0.73 | BRD4 (0.45) | CTSCCTSKCHRM1CREBBPBRD4 | |
| SCHEMBL19155121 | 0.70 | CTSC (0.55) | CTSCCTSKCHRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170266160-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | BOEHRINGER INGELHEIM INT (DE) | 2017-09-21 | — | — | US | disclosed |
| US-9713606-B2 | Methods for treating pulmonary emphysema using substituted 2-Aza-bicyclo[2.2.1]heptane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin C | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2017-07-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170266160-A1 | METHODS FOR TREATING PULMONARY EMPHYSEMA USING SUBSTITUTED 2-AZA-BICYCLO[2.2.1]HEPTANE-3-CARBOXYLIC ACID (BENZYL-CYANO-METHYL)-AMIDES INHIBITORS OF CATHEPSIN C | CTSC, CTSG, CTSZ | CTSC 1/4885CTSK 21/4885GSK3B 2428/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.